{"id":"injection-of-c3bs-cqr-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Immune effector cell-associated neurotoxicity syndrome (ICANS)"},{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Cytopenias"}]},"_chembl":{"chemblId":"CHEMBL2108490","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"C3BS-CQR-1 consists of genetically modified T cells derived from healthy donors that are equipped with chimeric antigen receptors (CARs) to recognize and eliminate cancer cells. The therapy is designed to be off-the-shelf, allowing for rapid administration without the need for patient-specific cell manufacturing. It represents an allogeneic approach to CAR-T cell immunotherapy, potentially offering broader accessibility compared to autologous CAR-T therapies.","oneSentence":"C3BS-CQR-1 is an allogeneic CAR-T cell therapy engineered to target and kill cancer cells expressing specific tumor antigens.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:15.059Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hematologic malignancies (specific indication under investigation in phase 3)"}]},"trialDetails":[{"nctId":"NCT01768702","phase":"PHASE3","title":"Safety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure.","status":"COMPLETED","sponsor":"Celyad Oncology SA","startDate":"2012-11","conditions":"Heart Failure","enrollment":315},{"nctId":"NCT02317458","phase":"PHASE3","title":"Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-2) Trial - THE CHART-2 TRIAL","status":"UNKNOWN","sponsor":"Celyad Oncology SA","startDate":"2017-06","conditions":"Heart Failure","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Injection of C3BS-CQR-1","genericName":"Injection of C3BS-CQR-1","companyName":"Celyad Oncology SA","companyId":"celyad-oncology-sa","modality":"Biologic","firstApprovalDate":"","aiSummary":"C3BS-CQR-1 is an allogeneic CAR-T cell therapy engineered to target and kill cancer cells expressing specific tumor antigens. Used for Hematologic malignancies (specific indication under investigation in phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}